# Pizarra — PT-pseudo_c7277954c60f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c7277954c60f
Task: 1

Encounter: Urology - outpatient on 18 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 9.8 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.073 ng/mL²
  - PSA velocity: 1.0 ng/mL/yr
  - Prior PSA: 8.6 ng/mL
  - Prostate volume: 134.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5260261 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30)
  - Problem list / PMHx: Obesity (BMI >30)
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.8 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 134 mL. csPCa 0.53.

Vitals: weight 74 kg, height 176 cm, BMI 23.9, BP 125/82 mmHg, HR 86 bpm. Smoking: Ex-smoker (12 pack-yr, quit 2017).

Chief complaint: Specialist evaluation requested to interpret recent multiparametric imaging results and address a steadily ascending PSA trajectory.

History: At 54 years of age, this retired shopkeeper shares a household with his unmarried partner and seeks re-evaluation for a persistently rising PSA curve. Lower urinary tract complaints are minimal, requiring no drug therapy. Physical activity includes biweekly home weight training, while alcohol consumption remains limited to one unit weekly. Tobacco cessation occurred in 2017 after a 12 pack-year exposure. Vision has progressively worsened over recent years, mandating large-print formats for all clinical documentation. Medical history includes obesity (BMI >30), stable COPD requiring periodic pulmonary function testing, and a recently completed endocrine assessment for thyroid screening. He explicitly denies bone discomfort, haematuria, or unexplained weight loss, maintaining overall stability throughout the diagnostic phase.

Physical examination: Genital assessment unremarkable; per rectum, digital rectal examination confirms a normal DRE. The gland appears symmetrically enlarged with a smooth, rubbery texture, devoid of palpable nodules or asymmetry. Systemic evaluation shows stable vital signs, absent lymphadenopathy, and no indicators of broader illness.

Patient info: retired shopkeeper; Living with partner (unmarried); Lives with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 1 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.24   (95% CI 0.05-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.23  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 1.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=0.0, psa=9.8, age=54.0, psad=0.073, dre_ord=0.0, vol=134.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.0 ng/mL/yr) against the high PSA level (9.8 ng/mL), which suggests a more aggressive trajectory than a static value. It also could not incorporate the full mpMRI report findings (beyond the PI-RADS 2) or the specific details from the PSA history or lab panel that might modify the risk profile. Finally, it could not assess the clinical significance of the csPCa predicted probability (0.526) in the context of the PI-RADS 2 score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.45 +/- 0.24), indicating high uncertainty. This uncertainty is likely due to the lack of crucial context. Specifically, the prior cannot account for the rising PSA trajectory (velocity of 1.0 ng/mL/yr), which increases suspicion. Furthermore, the PI-RADS 2 score is low, but the PSA is high (9.8 ng/mL), creating a potential internal contradiction that the prior, which only saw the static values, cannot resolve. The 'discuss' tier suggests the panel is ambiguous, but the true clinical picture might be clearer once the MRI prose or PSA trend is viewed.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features despite PI-RADS 2, it would increase the need for biopsy.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend is significantly steeper than the 1.0 ng/mL/yr velocity, it would increase the need for biopsy.
  <document> laboratory results (full panel) -> If the lab panel shows any markers (e.g., inflammation, other cancers) that alter the risk stratification, it would change the decision.
  <document> previous GP / urology consultation notes -> If prior notes mention any specific concerns or previous workup that informs the current decision pathway, it would refine the approach.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_c7277954c60f", "radiology_report": "Subject: Multiparametric MRI Prostate | Facility: Amsterdam UMC, AMC | Date: 15 Feb 2025\n\nClinical indication: Elevated PSA at 9.8 ng/mL, obtained for routine surveillance imaging.\n\nFINDINGS:\nThe gland exhibits marked hypertrophy, spanning roughly 5.8 × 5.2 × 4.6 cm and culminating in a total volume of 134.0 mL. Transition zone changes feature extensive benign nodular hyperplasia; the enlarged median lobe presses gently against the bladder base. Peripheral zone architecture remains uniform with standard T2 signal characteristics and absent restricted diffusion. Scanning reveals no focal abnormality warranting a PI-RADS 3 or greater classification. Contrast kinetics appear symmetric without suspicious enhancement. Seminal vesicles retain normal morphology. Capsular integrity is intact, and no suspicious lymph nodes are visualized.\n\nIMPRESSION:\nProstatic hypertrophy (total volume 134.0 mL) lacking a PI-RADS 3+ focus.\nPI-RADS 2.\nPSA density: 0.073.\ncsPCa probability 0.5260261."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_c7277954c60f", "psa_trend": [{"date": "Jan 2024", "val": 1.1}, {"date": "May 2024", "val": 2.9}, {"date": "Aug 2024", "val": 6.0}, {"date": "Nov 2024", "val": 3.8}, {"date": "Feb 2025", "val": 9.8}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_c7277954c60f", "laboratory_results": [{"name": "PSA", "val": "9.8 ng/mL", "date": "27 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.97 ng/mL", "date": "27 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "20%", "date": "27 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "16.5 g/dL", "date": "27 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.7 x10^9/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "324 x10^9/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "78 umol/L", "date": "27 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "27 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.1 nmol/L", "date": "27 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "50 U/L", "date": "27 Jan 2025", "flag": ""}, {"name": "LDH", "val": "184 U/L", "date": "27 Jan 2025", "flag": ""}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_c7277954c60f", "previous_notes": [{"date": "28 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "28 Aug 2023 consultation noted mild urinary hesitancy with minimal patient concern. Initial serum PSA measured 6.1 ng/mL. Subsequent testing in early 2024 demonstrated a progressive upward trend, leading to this current urological referral for comprehensive assessment."}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PSA: 9.8 ng/mL (High value)
  PSA velocity: 1.0 ng/mL/yr (Ascending trajectory)
  PSA trend: A significant rise from 1.1 ng/mL in Jan 2024 to 9.8 ng/mL in Feb 2025.
  
  AGAINST sampling this patient now:
  mpMRI: PI-RADS 2 (Low risk)
  mpMRI: No focal abnormality warranting a PI-RADS 3 or greater classification.
  DRE: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)

WHERE THIS LEANS
  The evidence strongly suggests a need for further investigation due to the significant and accelerating PSA rise (velocity of 1.0 ng/mL/yr) despite a low-risk MRI finding (PI-RADS 2). This contradicts the statistical prior of 'NO BIOPSY' by emphasizing the dynamic clinical data.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly suggests a need for further investigation due to the significant and accelerating PSA rise (velocity of 1.0 ng/mL/yr) despite a low-risk MRI finding (PI-RADS 2). This dynamic clinical data overrides the low-risk imaging score and the statistical prior suggesting deferral. The decision is driven by the high PSA value of 9.8 ng/mL and the rising PSA velocity of 1.0 ng/mL/yr.

Variables that carried weight: age=noted, psa=decisive, vol=noted, psad=noted, pirads=noted, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
